Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on January 26, 2021. The report details a strategic realignment plan approved by the Board of Directors on January 31, 2021, aimed at reducing operating costs and aligning the workforce with ongoing business needs.
Key Financial Metrics and Material Changes
- Workforce Reduction: The Company plans to reduce its workforce by 7 employees, representing approximately 58% of the total workforce. The plan is expected to be substantially complete by March 31, 2021.
- Estimated Costs: The Company estimates one-time employee-related expenses of approximately $1.2 million. This includes severance benefits, healthcare insurance premiums, and outplacement assistance.
- Payment Timing: The majority of these costs are anticipated to be paid during the 2021 fiscal year.
- Executive Departure: Kevin Peters, M.D., Chief Scientific Officer and Chief Medical Officer, was notified of his termination as part of the reduction in force.
- Executive Compensation Changes:
- Joseph Gardner, Ph.D. (President and Founder): Entered into a second amendment to his employment agreement. Severance terms were updated to include up to 12 months of base salary and medical benefits upon termination without cause, or 1.5 times salary plus target incentive compensation in the event of a change in control within 15 months.
- Retention Payments: The Board approved cash retention payments for remaining employees to incentivize retention. Dr. Gardner is eligible for $216,300, and Regina Marek (VP of Finance) is eligible for $139,050. Payments are contingent on shareholder approval of a strategic transaction and continued employment.
Guidance, Outlook, and Risks
The filing does not provide specific revenue, profit, or cash flow guidance. Management commentary focuses on the necessity of cost reduction to align with business needs. Key risks and contingencies include:
- Cost Variability: Actual costs may differ from the $1.2 million estimate due to assumptions or unforeseen events.
- Additional Costs: The Company may incur additional significant costs not currently contemplated, which would require an amended filing.
- Strategic Transaction Dependency: A portion of the retention payments for executives is contingent upon shareholder approval of a strategic transaction.
Important Facts for Investor Verification
- Verify the exact number of employees remaining post-reduction to confirm the 58% reduction figure.
- Monitor the Company's cash position to ensure it can cover the estimated $1.2 million in one-time costs during 2021.
- Track the status of the "strategic transaction" referenced in the retention payment terms for executives.
- Confirm the effective date of Dr. Peters' departure and the terms of the transition services agreement.
- Review the full text of Exhibit 10.1 for the complete details of Dr. Gardner's amended employment agreement.